Lumida
/LMRI
⌘K
LMRI

LMRI

LMRI
$11.14USD↓-0.54%-0.06 today

MARKET CAP

1.1B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$11 – $11

52W RANGE

$6
$19

AI Summary

Stalk
StalkMedium

LMRI remains in a Stage 2 advance with key EMAs sloping up. The recent corrective pullback into the 9/21 EMA zone has not breached intermediate structure, sustaining a medium-term bullish bias. However, short-term signals lack a clear reversal, so we defer execution and stalk for a decisive pullback interaction at the EMAs before engaging.

  • ↑Q1 revenue $253 M (+3% YoY), advanced modalities grew 7%.
  • ↑PET volumes jumped 23.1% and MRI rose 8.2% YoY.
  • ↓Negative profitability score; operating cash flow ~$3 M pressures margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Lumexa Imaging Holdings (NASDAQ: LMRI) operates within the outpatient imaging services sector and specializes in advanced imaging modalities such as PET and MRI. The company’s strategy involves expanding its services through de novo openings and strategic partnerships to meet the growing demand for timely and efficient outpatient imaging solutions. With a significant national footprint of over 190 centers, including recent expansions in key states, Lumexa is positioned to capitalize on the continuous shift towards outpatient care amid evolving healthcare dynamics.

Bull says

  • ↑Q1 revenue $253 M (+3% YoY), advanced modalities grew 7%.
  • ↑PET volumes jumped 23.1% and MRI rose 8.2% YoY.
  • ↑On track to open 8–10 new centers; two launches in Q1.
  • ↑UPMC joint venture to expand reach in key markets.
  • ↑AI FastScan boosts throughput ~40%, adding scheduling capacity.
  • ↑Positive momentum and quality factors underpin growth outlook.

Bear says

  • ↓Negative profitability score; operating cash flow ~$3 M pressures margins.
  • ↓Leverage ratio ~1.85× heightens risk in a rising rate environment.
  • ↓Q1 EBITDA hit by $4 M weather-related volume disruptions.
  • ↓Negative dividend yield and $20–28 M in stock comp expenses strain cash.
  • ↓Two recent acquisitions may deliver minimal 2026 revenue contribution.
  • ↓High volatility and interest-rate sensitivity undermine investor confidence.

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 05-30-2026neutral

Transcript signals

Bull points

  • For the fourth quarter, it was $66.8 million.
  • We generated consolidated revenue of $267.7 million, up 7.9% over Q4 of last year.
  • Adjusted EBITDA of 63.8 million represented an 18.6% increase over Q4 of last year and delivered a 23.8% adjusted EBITDA margin.

Bear points

  • Yeah, the growth rate was 10.6% year over year.
  • Expenses related to the refinancing of our debt and other transaction costs in our IPO year resulted in a gap net loss of $28.7 million for the quarter, compared to a net loss of $25.1 compared to 53.7 million in the same period last year, representing an increase of 18.6%
  • we believe our strong Q4 New Jersey, Texas, and three other southern states were impacted in Q1 by storms, causing some impact volumes.
Read full transcript analysis ›